Introduction: Response to mesenchymal-epithelial transition (MET) inhibitors in NSCLC with mesenchymal-epithelial transition gene (MET) exon 14 skipping (METex14) has fueled molecular screening efforts and the search for optimal therapies. However, further work is needed to refine the clinicopathologic and prognostic implications of METex14 skipping.
Introduction
Precision medicine has been defined as the evidencebased management of advanced NSCLC. 1 Although remarkable advances have been achieved in the treatment of patients with lung adenocarcinoma whose tumors harbor targetable alterations in EGFR and anaplastic lymphoma kinase gene (ALK) rearrangements, [2] [3] [4] [5] platinum-based cytotoxic chemotherapy remains the standard therapy for advanced or metastatic lung cancers in which targetable genomic alterations are not identified. 6 Constant effort is essential to discover additional targetable genomic alterations in NSCLC.
Emerging tyrosine kinase inhibitors have shown impressive results in ROS1 rearrangements, BRAF V600E mutations, ret proto-oncogene (RET) rearrangements, erb-b2 receptor tyrosine kinase 2 (ERBB2) mutations, and mesenchymal-epithelial transition gene (MET) exon 14 skipping (METex14) mutations.
1 METex14 skipping as a targetable genomic alteration has been reported in lung cancer and is present in 4.3% of lung adenocarcinomas in The Cancer Genome Atlas data set.
7 Small-molecule mesenchymal-epithelial transition (MET) tyrosine kinase inhibitors such as crizotinib and cabozantinib have shown remarkable initial responses in patients with lung adenocarcinoma harboring METex14 skipping. [8] [9] [10] However, screening for METex14 skipping has yet to become widely incorporated into routine clinical practice. 11 In this context, we aimed to define the clinicopathologic characteristics of lung adenocarcinoma harboring METex14 skipping mutations as potential target candidates for future screening strategies. In addition, we aimed to investigate the effect of MET inhibitors including small molecules and small interfering RNA (siRNA) that target the junction of skipping in METex14 skipping-positive cell lines.
Materials and Methods

Patients and Clinical Characteristics
Between February 2007 and May 2014, patients who underwent a surgical procedure for NSCLC were selected from a database at Samsung Medical Center in Seoul, Republic of Korea. We identified 94 cases from a total of 795 lung adenocarcinomas that were negative for alterations in KRAS, EGFR, and ALK by prior testing. These 94 cases were screened for the presence of RET and ROS1 fusion transcripts by direct digital transcript profiling by using the NanoString nCounter technology as described previously, 12, 13 leading to the identification of 70 quintuple-negative (EGFR-negative/KRASnegative/ALK-negative/ROS1-negative/RET-negative) tumors. Of these, formalin-fixed paraffin-embedded (FFPE) specimens of 45 tumors were available for testing by quantitative reverse-transcriptase (qRT) polymerase chain reaction (PCR) (qRT-PCR) with probes spanning the junction from exon 13 to 15, a fusion transcript caused by METex14 skipping mutation. These 45 FFPE specimens of surgically resected primary or metastatic tumors included 42 primary lung tumors, two brain metastatic tumors, and one pleural metastatic tumor. Among 45 specimens, 42 cases had available paraffin blocks for cellular MET immunohistochemical (IHC) testing, 33 cases for hepatocyte growth factor (HGF) IHC testing, 31 cases for MDM2 proto-oncogene (MDM2) IHC testing, and 33 cases for p53 IHC testing.
To identify the clinicopathologic characteristics of patients on the driver mutations, we analyzed the demographic data and clinical outcomes of patients with lung adenocarcinoma harboring METex14 skipping and compared their data with the data of patients with lung adenocarcinoma harboring EGFR mutation (n ¼ 56), ALK fusion (n ¼ 145), ROS1 fusion (n ¼ 9), RET fusion (n ¼ 15), and pan-negative tumors (n ¼ 28) by using independent data sets of Samsung Medical Center. This study was approved by the institutional review board of Samsung Medical Center.
qPCR, qRT-PCR, and Sanger Sequencing
Genomic DNA and RNA were isolated from FFPE tumor specimens for METex14 skipping-specific quantitative PCR (qPCR) and MET copy number qPCR. All qPCR reactions were performed in triplicate by using the SYBR green method (Thermo Fisher Scientific, Waltham, MA). The PCR conditions were as follows: preheating at 50 C for 2 minutes, 95 C for 10 minutes, 40 cycles at 95 C for 15 seconds, and 60 C for 1 minute. The primer sequences are listed in Supplementary Tables 1 to 3 . For the detection of METex14 skipping status, we designed a forward primer spanning the junction from exon 13 to 15 and another primer set located within exon 14 for wild-type MET. MET type-specific relative quantification was conducted by using the DCt method with the glucuronidase, beta gene (GUSB) gene as a reference. MET copy numbers were calculated by comparison with albumin gene (ALB), located at 4q11-q13, and normalized to normal tissue genomic DNA. Sanger sequencing was performed to confirm METex14 skipping by using primer sets targeting exon 14 splice donor and acceptor sites. All PCR products were purified with PCR purification kits and directly sequenced by standard procedures using forward and reverse primers. In addition, we retrospectively evaluated the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutations in patients with METex14 skipping by using Sanger sequencing to evaluate the incidence of coexistence.
Pathologic Characteristics
IHC staining was performed on 3-mm-thick FFPE tissue sections. The sections were deparaffinized and rehydrated, and antigen retrieval was performed for 40 minutes in citrate buffer (pH 6.1) at 95 C. Diaminobenzidine was used as the chromogen, and the sections were counterstained with hematoxylin. The BenchMark XT automated slide processing system (Ventana Medical Systems, Tucson, AZ) was utilized. The PATHWAY anti-MET (sp44) antibody Ventana Medical Systems) was used for MET IHC staining. IHC data were categorized according the following staining scores: 0, negative; 1, weak; 2, moderate; and 3, strong. In addition, the cytoplasmic and membranous staining patterns were evaluated. MET overexpression was defined as (1) a score of 2þ or 3þ (by membranous and cytoplasmic interpretation) or (2) a score of 3þ (by membranous interpretation alone). The HGF antibody (AF-294-NA [R&D Systems, Inc., Minneapolis, MN]) in a 1:10 dilution was used for HGF IHC staining. The anti-goat N-Histofine Simple Stain Max Pro detection reagent (414162F [Nichirei, Tokyo, Japan]) was applied according to the manufacturers' instructions. Each sample was given a categorical score based on the percentage of positive cells (0, 10%; 1, 11%-25%; 2, 26%-50%; and 3þ, !50%) and the intensity of the staining (0, negative; 1þ, weak; 2þ, intermediate; and 3þ, strong). A tumor was considered HGF positive when a score of 1þ or higher was assigned. MDM2 antibody (SMP14 [NeoMarker, Fremont, CA]) (in a 1:50 dilution) was used. Each sample was scored on the basis of the percentage of positive lesional nuclei: 0, 0%; 1þ, 1% to 25%; 2þ, 26% to 50%; and 3þ, more than 50%. A tumor was considered MDM2 positive when a score of 2þ or higher was assigned. Only nuclear staining was scored as positive. Tumor protein p53 antibody (Invitrogen, New York, NY) (1:4000 dilution) was used with an autoimmunostainer (Leica Bond Polymer Refine detection kit and the Leica Bond-Max staining system [Leica Microsystems, Wetzlar, Germany]). In assessing positivity, nuclear staining greater than 10% was regarded as positive.
Cell Culture, siRNA Knockdown, Cell Proliferation Assay, and Western Blotting
To investigate the function of METex14 skipping, we determined whether knockdown of the METex14 skipping splice variant affects MET expression and phosphorylation levels in the METex14 skipping-positive cell lines, including H596 (pulmonary adenosquamous carcinoma, METex14 skipped, and PIK3CA mutated) and Hs746T (gastric adenocarcinoma, METex14 skipped, and MET amplified). MKN-45 (gastric cancer, wild-type MET with high MET expression) and 293FT (human embryonic kidney, wild-type MET with low MET expression) were used as negative controls.
H596, Hs746T, MKN-45, and 293FT cell lines were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's modified Eagle's medium and Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum at 37 C in 5% CO 2 . All of the cell lines used were authenticated by short tandem repeat profiling before a new series of experiments was begun and were kept in culture for no more than 3 months. H596 cells were treated with siRNAs or a combination of the MET inhibitor crizotinib (Selleck Chemicals, Houston, TX) with siRNAs in the presence of recombinant human HGF (Sigma-Aldrich, St. Louis, MO). The siRNAs were designed on the basis of the target sequence and directed against the junction of METex14 skipping. siRNA transfection for knockdown of the METex14 splice variant was performed with Lipofectamine RNAiMAX reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. The sequences are provided in Supplementary Table 4 . Total protein and RNA were collected for Western blot analysis and qRT-PCR, respectively. Cells were grown in complete medium and transfected with siRNA a day after seeding. Two or four days later, the surviving cells were quantified by WST-1 staining (Roche, Basel, Switzerland).
Immunoblotting was performed with antibodies against the following proteins 
Statistical Analyses
For analysis of the relationship between clinicopathologic characteristics and MET overexpression, the Pearson c 2 test, Fisher's exact test, or the CochranArmitage trend test were used. Freedom from recurrence and overall survival (OS) were defined as the period between initial diagnosis of lung cancer and either recurrence or death. Survival curves were estimated by the Kaplan-Meier method, and differences in survival were assessed by the log-rank test. Multivariate analyses for prognostic factors of freedom from recurrence or OS were conducted by using a Cox proportional hazards model. Statistical Package for the Social Sciences software, version 18.0 (SPSS, Chicago, IL) was used for all statistical analyses. All tests were two sided, and p values less than 0.05 were considered statistically significant.
Results
Clinicopathologic Characteristics of METex14
Skipping Compared with EGFR Mutation, ALK Fusion, ROS1 Fusion, RET Fusion, and Pan-Negative Lung Adenocarcinoma
Among the 45 patients with quintuple-negative (EGFR-negative/KRAS-negative/ALK-negative/ROS1-negative/RET-negative) lung adenocarcinomas, 17 (37.8%) were identified by using RT-PCR (Supplementary Table 5 ) and 12 were confirmed to have METex14 skipping mutations by Sanger sequencing (Fig. 1A) . The overall prevalence of METex14 skipping in lung adenocarcinomas was 2.1% (17 of 795). Table 1 Table 5 ). Nine (52.9%), three (17.6%), and five patients (29.4%) had pathologic stage I, II, and IIIA disease, respectively. No patient was at stage IV. Postoperative therapy was performed in 10 patients (58.8%). No patient was treated with anti-MET targeted therapy.
During a median of 22 months (range 0-184), 10 of 17 patients suffered from recurrences, including locoregional recurrence (n ¼ 3) and distant metastasis with or without locoregional recurrence (n ¼ 7). The sites of locoregional recurrence were the intrathoracic lymph nodes (n ¼ 2) and pleura (n ¼ 1). The sites of distant metastasis were the lung (n ¼ 2), lung and rib (n ¼ 1), lung and pleura (n ¼ 1), pleura and rib (n ¼ 1), lung and adrenal gland (n ¼ 1), and lung and brain (n¼1). Recurrence pattern was not significantly different between tumors harboring METex14 skipping and pannegative tumors (data not shown). Among the patients harboring METex14 skipping, no one received anti-MET therapy upon recurrence. During the median survival of 28 months (range 1-184), two patients died.
Comparison of the Prognosis of Patients
Harboring METex14 Skipping, EGFR Mutation, ALK Fusion, ROS1 Fusion, RET Fusion, and Pan-Negative Lung Adenocarcinoma
None of the 17 patients with METex14 skipping received preoperative chemotherapy, radiation therapy, or postoperative targeted therapies, and all tumors were classified as pathologic stage I to IIIA; therefore, the comparison analysis was conducted in pathologic stages I to IIIA lung adenocarcinoma that was not treated with preoperative therapy or postoperative targeted therapy. Consequently, prognostic outcomes were analyzed in 17 patients harboring METex14 skipping, in addition to 49 patients with EGFR mutation, 89 patients with ALK fusion, eight patients with ROS1 fusion, 12 patients with RET fusion, and 20 patients with pan-negative lung adenocarcinoma.
In Kaplan-Meier analyses, patients harboring METex14 skipping tended to have a higher recurrence rate (p ¼ 0.004) ( Fig. 2A) . In multivariable analyses using a Cox proportional hazards model, patients with METex14 skipping had a higher recurrence rate than those with ALK fusion (versus METex14 skipping) (p ¼ 0.004, hazard ratio ¼ 0.283, 95% confidence interval [CI]: 0.119-0.670); however, the difference in OS was not significant between groups after adjustment for age, sex smoking status, and pathologic stage (ALK fusion versus METex14 skipping) (p ¼ 0.669, hazard ratio ¼ 0.679, 95% CI: 0.115-3.997) ( Table 2 ).
Pathologic Characteristics of METex14 Skipping
All 17 METex14 skipping-positive tumor specimens were from primary lung lesions, including 11 (64.7%) moderately differentiated and six (35.3%) poorly differentiated adenocarcinomas. The predominant growth patterns were acinar in nine cases (52.9%), solid in six (35.3%), and papillary in two (11.8%). Forty-two cases had available paraffin blocks for cellular MET IHC. Among the 42 patients with samples available for MET IHC testing, 100% with of METex14 skippingpositive tumors (15 of 15) showed higher than 2þ simultaneous membranous and cytoplasmic MET expression (Fig. 3) , whereas 29.6% (eight of 27) showed MET overexpression in METex14 skipping-negative tumors. The rate of MET overexpression was significantly higher in the METex14 skipping-positive group than in the METex14 skipping-negative group (p < 0.001). MET IHC testing for METex14 skipping mutations showed 100% (95% CI: 79.6-100) sensitivity and 70.4% (95% CI: 51.5-84.2) specificity. IHC for HGF, MDM2, and p53 was performed in 33, 31, and 33 patients, respectively. HGF protein expression was scored as 2þ in 13 Figure 2 . Kaplan-Meier survival curves for (A) freedom from recurrence and (B) overall survival based on driver mutations in patients with stages I to IIIA lung adenocarcinoma without preoperative treatment or targeted therapies. Pan-negative indicates negative status for EGFR mutation, anaplastic lymphoma kinase gene (ALK) fusion, ROS1, Ret Proto-Oncogene (RET) fusion, and mesenchymal-epithelial transition gene (MET) exon 14 skipping (METex14). 
Molecular Characteristics of METex14 Skipping
The molecular features of the 17 cases of METex14 skipping are described in Figure 1A and Supplementary  Table 7 . In all 17 cases, the METex14 skipping transcripts were identified by using MET type-specific relative quantification PCR. Although METex14 skipping transcripts were identified in two of 28 pan-negative cases, the DCt values (del/GUSB ratio) of RT-PCR for these samples were 0.00 and 0.01, respectively. To validate the METex14 skipping status, Sanger sequencing was performed in 12 cases harboring METex14 skipping. Among the 12 cases with genetic alterations, 11 distinct genomic sequence variants were found: six cases with 5 0 splice site indels and six with 3 0 splice-site point mutations and deletions (see Fig. 2 Fig. 2A ). We screened 14 siRNAs targeting the junction from exon 13 to 15 for sequence specificity (Supplementary Fig. 2B ) by transfection of each siRNA into METex14 skipping-positive cell lines. Of the 14 siRNA candidates, three produced strong, consistent, and reproducible knockdown of the METex14 skipping fusion mRNA (candidates 1, 10, 14 [ Supplementary  Fig. 2C]) .
Western blotting showed smaller MET protein in the two METex14 skipping-positive cell lines but not in the two cell lines with wild-type MET. Without the presence of HGF, Hs746T cells showed high expression and phosphorylation of MET, whereas H596 showed low expression and phosphorylation of MET (Fig. 4A) . Two of the three candidate siRNAs (1 and 10) inhibited MET expression and phosphorylation as well as downstream MAPK phosphorylation but not STAT3 or AKT phosphorylation in H596 cells (Fig. 4B) . In Hs746T cells, siRNAs 1 and 10 inhibited MET expression, MET phosphorylation, and downstream AKT phosphorylation but not STAT3 or MAPK phosphorylation. Possible off-target effects of the two siRNAs were evaluated by using 293FT and MKN-45 cells (see Fig. 4B ). As shown in Figure 1B , only siRNA 10 showed no effect on wild-type MET expression and downstream AKT phosphorylation in MKN-45 and 293FT cells. Moreover, ablation of MET signaling with siRNA 10 inhibited cell proliferation in H596 and Hs746T but not MKN-45 cells (Fig. 4C ). H596 cells with METex14 skipping and PIK3CA mutation lead to insensitivity to crizotinib monotherapy. 13 We examined the effect of combined ablation of METex14 skipping fusion forms using siRNA and crizotinib on cell proliferation in H596 cells. As shown in Figure 1D , concomitant treatment of crizotinib and METex14 skipping specific siRNA (10) showed a synergistic effect on cell proliferation in H596 cells.
Discussion
MET receptor can be activated through various mechanisms, including interaction with its ligand (HGF), genomic amplification, receptor-protein overexpression, point mutations, alternative splicing, and possibly chromosomal translocation. [14] [15] [16] METex14 skipping resulting from alternative splicing can occur through diverse genomic alterations involving the splice sites, resulting in in-frame skipping of the juxtamembrane domain encoded by METex14. Mutations in the METex14 RNA splice acceptor and donor site lead to exon skipping and deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase binding site, which decrease degradation of the resultant aberrant MET protein. [17] [18] [19] [20] as compared with the rates in the United States: 4.5% (eight of 178), 2.9% (205 of 7140), and 2.1% (18 of 873). 8, 10, 21, 22 The lower detection rate of METex14 skipping in our study could be due to the methodologic difference between RT-PCR-and next-generation sequencing-based analyses rather than ethnic differences.
Interestingly, METex14 skipping was identified in 37.8% of quintuple-negative lung (EGFR-negative/ KRAS-negative/ALK-negative/ROS1-negative/RET-negative) adenocarcinomas (17 of 45) in the present study. This incidence is higher than that from a previous study, which reported that the prevalence of METex14 skipping was 19% (10 of 54 NSCLC cases) in Western patients without any alterations of EGFR, KRAS, BRAF, ERBB2, ALK, or ROS1. 23 METex14 skipping has been reported to be mutually exclusive of other known driver gene alterations 8, 18, 23 ; thus, whereas the incidence of EGFR mutation in lung adenocarcinoma is higher in East Asian populations than in Western populations, 24 ,25 the relative frequency of METex14 skipping among quintuple-negative lung adenocarcinomas (EGFRnegative/KRAS-negative/ALK-negative/ROS1-negative/ RET-negative) could be higher in East Asian populations with lung adenocarcinoma. Therefore, it is meaningful to screen for METex14 skipping mutations in East Asian patients without other oncogenic driver mutations.
Regarding the clinicopathologic characteristics of METex14 skipping-positive patients, the median age was 73 years, which is significantly higher than that of patients with the EGFR mutation, ALK fusion, ROS1 fusion, and RET fusion in the present study (see Supplementary Fig. 1 ). This result is in line with that from a previous study reporting that METex14 skipping positivity in patients with NSCLC was significantly associated with advanced age. 19, 22 It is known that mutational events of METex14 skipping are frequent and potentially targetable events in pulmonary sarcomatoid carcinoma. 26 Regarding adenocarcinoma, in accordance with a previous study, 19 the acinar subtype of adenocarcinoma was predominant, followed by the solid subtype in lung adenocarcinoma with METex14 skipping. However, there are no pathognomonic histologic findings for METex14 skipping in lung adenocarcinoma. Although the role of IHC in detecting METex14 skipping is yet to be established, MET IHC for METex14 skipping showed 100% sensitivity and 70.4% specificity in the present study. This result indicates that MET IHC could be a good initial screening test for performing molecular testing of METex14 skipping in lung cancer. 27 Several studies have reported that lung cancers harboring METex14 skipping can respond dramatically to small-molecule MET inhibitors such as crizotinib and cabozantinib. [8] [9] [10] 26 In addition, the interim analysis from the METex14 skipping cohort reported that crizotinib has a generally tolerable adverse effect profile consistent with that previously reported for patients with NSCLC and ALK fusion or ROS1 fusion. However, none of the patients with tumors and METex14 skipping in the present study received MET-directed therapy because it was a retrospective analysis using archived tissues. Consequently, the prognostic analyses in the present study were performed among patients with stages I to IIIA lung adenocarcinoma without properly targeted therapies. The 5-year OS rate was 80% in the 17 patients in the present study who were classified as having surgically resected stage I to IIIA disease without preoperative treatments or appropriate targeted therapies. On the other hand, the 5-year OS was close to 0% in a previous study conducted in an East Asian population classified as having stage IV disease without appropriate targeted therapies. 17 In the present study, we observed that 70% of recurrences after surgery for the lung adenocarcinoma harboring METex14 skipping were distant metastasis, including pulmonary recurrences. Interestingly, during the study period, brain metastasis occurred in only one patient among those with METex14 skipping. This result was different from that for ALK-positive NSCLC, because the central nervous system is known to be a common site of progression for patients with ALK-positive NSCLC treated with crizotinib. 28 Regarding the differences in prognosis between oncogenic drivers, the differences of OS were not significant in multivariate analyses after adjustment for covariates, including pathologic stage. This result is in line with a previous study reporting that mutation status was not a major risk factor in terms of OS in patients with stage IV METex14 mutation-positive lung cancer who received no specific anti-MET therapy. 25 Further studies including analyses of clinical outcomes in a larger sample size are needed in this regard.
We performed in vitro experiments to evaluate the effect of genetic ablation targeting of the junction of METex14 skipping by using siRNA. We used siRNA that targeted the junction of METex14 skipping, which is a difference from a previous study that used siRNA targeting wild MET protein, which is inhibitory through both AKT and MAPK pathways in cells with METex14 skipping. 26 In the present study, we observed that siRNA targeting METex14 skipping protein was inhibitory only through the AKT pathway in Hs746T cells and only through the MAPK pathway in H596 cells. These results indicate that siRNA targeting METex14-skipped protein may reduce unwanted off-target toxicities. 29 In addition, the in vitro study in the present article focused on the fact that the combination of crizotinib and METex14 skipping specific siRNA exerts a synergistic effect on reducing cell proliferation in H596 cells. It can be inferred that METex14 skipping-specific siRNA could have a potent effect against in vitro models of acquired resistance to crizotinib in H596 cells.
The present study has several limitations inherent in its retrospective design, small sample size, and insufficient follow-up period. Moreover, the results of the present study could have been skewed by selection bias, because the tumors used in the prognostic analyses were limited to surgically resected stage I to IIIA lung adenocarcinomas. Therefore, we cannot draw a definitive conclusion from the present study. Finally, we analyzed several phenomena by using in vitro experiments; however, we could not explain the differences between siRNA mechanisms targeting METex14 skipping and those targeting wild MET in the present study. In vivo studies will be required to ascertain the oncogenicity of METex14 skipping and the effects of small-molecule MET inhibitors, including siRNA, that target the junction of METex14 skipping.
In conclusion, the prevalence of METex14 skipping was quite high in East Asian patients without other driver mutations in lung adenocarcinomas. METex14 skipping was associated with old age, acinar or solid histologic type, and high MET IHC expression. The prognosis of patients with METex14 skipping was similar to that of patients with major driver mutations. siRNA targeting the junction of METex14 skipping could inhibit MET-driven signaling pathways in cells with METex14 skipping.
